Finding medicines that block SGF29, a protein that helps leukemia grow
Screening for Inhibitors of the Chromatin Reader SGF29
Looking for new drugs that block the SGF29 protein to slow or stop acute myeloid leukemia in people with AML.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11317218 on NIH RePORTER |
What this research studies
Researchers will screen large collections of compounds in the lab to find molecules that block SGF29, a chromatin reader that helps turn on leukemia-promoting genes. Promising hits will be tested in leukemia cell lines and in preclinical models to see whether they reduce oncogene activity and stop leukemia growth. The team will use multiple lab assays they developed to measure SGF29 activity and effects on key AML drivers like MYC and HOX proteins. If leads look good, the work could move toward drug development and future clinical testing across diverse AML subtypes.
Who could benefit from this research
Good fit: The eventual clinical candidates would be people diagnosed with AML, particularly those whose leukemia shows evidence of SGF29-dependent gene activity or MYC/HOX-driven signatures.
Not a fit: Patients with blood cancers not driven by SGF29-related pathways or who need urgent standard-of-care treatment are less likely to benefit from this early-stage work.
Why it matters
Potential benefit: If successful, this work could produce new targeted therapies that suppress leukemia-driving genes and help many patients with AML, including those whose disease has varied mutations.
How similar studies have performed: Preclinical studies including genetic loss of SGF29 have blocked leukemia growth, but small-molecule inhibitors targeting SGF29 are novel and have not yet been proven in patients.
Where this research is happening
La Jolla, United States
- Sanford Burnham Prebys Medical Discovery Institute — La Jolla, United States (Active)
Researchers
- Principal investigator: Deshpande, Aniruddha J. — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Deshpande, Aniruddha J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.